Top Tweets for #DrugsofToday
#DrugsofToday >> Learn how #Imeglimin, a medication currently under investigation in the US & approved in Japan, is a first-in-its-class medication with a mechanism that targets multiple pathways to provide glycemic control. https://t.co/HhVOQAsGnn
#DrugsofToday >> Learn how #infigratinib from @BridgeBioPharma received accelerated @US_FDA approval for adults with cholangiocarcinoma (CCA), a fatal liver #cancer.
Read the latest issue: https://t.co/YAiO8LSS3g
#DrugsofToday >> Learn the efficacy of about #Bimekizumab from @UCBUSA in treating #psoriasis patients and how it has demonstrated a consistent safety profile and high tolerability. Read the latest issue at https://t.co/aDHxywdbZv.
#DrugsofToday >> Cervical cancer is one of the most common gynecological malignancies but #tisotumab is a potential novel treatment that could induce long-lasting remission.
Check out the latest issue to learn more: https://t.co/LYzpkF74Bo
#cervicalcancer
#DrugsofToday >> Nemolizumab demonstrates great efficacy in the treatment of itching associated with #atopicdermatitis.
Learn more in our free sample April issue: https://t.co/UL2vPMHo5r
#pharma
#DrugsofToday >> #Dapagliflozin shown to reduce chronic #kidneydisease progression in patients with and without #diabetes. Discover more: https://t.co/1OiI9V704y #biotech #pharma
#DrugsofToday >> #Telitacicept received its first approval for #SLE in #China. @Clarivate experts review the background of this novel recombinant fusion protein.
Read more in the January issue: https://t.co/LsmLjh0AwU
#autoimmune #biotech #pharma
Harry's review article "Casimersen for Duchenne muscular dystrophy" is featured in the latest issue of #DrugsofToday @clarivate, summarizing the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety. @WCHRIUofA @UAlberta_FoMD
#DrugsofToday >> In the latest issue, @Clarivate experts take a look at #Casimersen, a phosphorodiamidate morpholino oligomer recently approved for the treatment of #DuchenneMuscularDystrophy. Learn more: https://t.co/veArxtgVvv
#drugdevelopment #lifesciences #DMD
#DrugsofToday >> In the latest issue, @Clarivate experts take a look at #Casimersen, a phosphorodiamidate morpholino oligomer recently approved for the treatment of #DuchenneMuscularDystrophy. Learn more: https://t.co/veArxtgVvv
#drugdevelopment #lifesciences #DMD
In the latest issue of #DrugsofToday, we examine the data of #neuroblastoma treatment with the anti-GD2 monoclonal antibody #naxitamab. (URL)
#YmAbs #drugdevelopment #biotech #pharma
Interested in learning more about #selpercatinib, the first approved therapy for #RET-altered non-small cell lung cancer and certain types of #thyroidcancer? Learn more in our #DrugsofToday review: https://t.co/v7iWEITXDH
#loxooncology #clinicaldevelopment #NSCLC #RETmutations
The anti-HER2 antibody #margetuximab is a new option for #breastcancer treatment – see our review in #DrugsofToday: https://t.co/eELKqglga6
#clinicaldevelopment #breastcancer #MacroGenics #HER2
In the latest issue of #DrugsofToday, we look at #enarodustat, an oral HIF prolyl hydroxylase inhibitor developed for treating #anemia associated with chronic #kidneydisease. Learn more: https://t.co/hcZBkAYmP7 #JapanTobacco #DrugDevelopment #CKD
Lasmiditan, a new treatment option for migraine: see our review of the data in Drugs of Today: https://t.co/OWh1ani2R9
#drugsoftoday #drugdevelopment #clinicaldevelopment #lifesciences #lasmiditan #migraine
Silencing ALAS1 for prevention of acute porphyria – see our review of Givosiran in the new issue of Drugs of Today: https://t.co/UTZnMcxNLa
#drugsoftoday #drugdevelopment #Alnylam #lifesciences # givosiran #porphyria
Fedratinib is an alternative JAK2 inhibitor for ruxolitinib-resistant or -intolerant myelofibrosis: https://t.co/EwjAIJhWwf
#drugsoftoday #Celgene # fedratinib #myelofibrosis #drugdevelopment #clinicaldevelopment #lifesciences
Tegoprazan is a new option to treat gastroesophageal reflux disease – review its profile now in Drugs of Today: https://t.co/XigcorT4HK
#drugsoftoday #drugdevelopment #clinicaldevelopment #lifesciences #tegoprazan #GERD #RaQualia
Can Avapritinib succeed where other GIST treatments fail? We review the data: https://t.co/nQucjgEAm1
#BlueprintMeds #drugsoftoday #drugdevelopment #lifesciences #drugdevelopment #avapritinib #GIST
See the evidence on zanubrutinib, a second generation BTK inhibitor for mantle-cell lymphoma, in the August issue: https://t.co/q09koT3GIM
#drugsoftoday #drugdevelopment #BeiGene #lifesciences #zanubrutinib #mantlecelllymphoma #lymphoma
How can the first oral CGRP antagonist improve migraine treatment? See our review of ubrogepant: https://t.co/AlnrLfar9y
#Allergan #drugsoftoday #drugdevelopment #ubrogepant #migraine #headache #migrainetreatment
Last Seen Hashtags on Sotwe
Teenage() +filter:native_video
Seen from United States
momson filter:native_video
Seen from Netherlands
pphoki
Seen from Indonesia
freakshit
Seen from Netherlands
圣水视频
Seen from Japan
omegle Momson() +filter:native_video
incest Indonesia
Seen from Indonesia
直男
kadikoytravesti
Seen from Turkey
男娘
Seen from Vietnam
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
119.2M followers
Cristiano Ronaldo
@cristiano
112M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.2M followers
KATY PERRY
@katyperry
88.4M followers
Taylor Swift
@taylorswift13
82.3M followers
Lady Gaga
@ladygaga
73.8M followers
Virat Kohli
@imvkohli
71.1M followers
Kim Kardashian
@kimkardashian
70.2M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.3M followers
Neymar Jr
@neymarjr
64M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.5M followers
X
@x
60.8M followers